|
|
|
|
ConsulTech GmbH
|
|
ConsulTech GmbH
|
|
ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform
Laval, Quebec, January 4, 2022 – Altasciences, an integrated
CRO/CDMO offering pharmaceutical and biotechnology companies a seamless
solution to early-stage drug development from lead candidate selection
to clinical proof of concept, announced today the completed acquisition
of Sinclair Research, a preclinical CRO located in the Midwest.
Complementing existing locations on the East and West Coast, the new
site will facilitate even greater access to Altasciences’ preclinical
services across the US.
More info >> |
|
 |
White Papers |
 |
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
PRA Health Sciences (PRA)
Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >> |
|
|
|
